Moderna up 16% on positive comments on vaccine platform

Feb. 07, 2020 3:52 PM ETModerna, Inc. (MRNA), ALNYALNY, MRNABy: Douglas W. House, SA News Editor7 Comments
  • Investors are maintaining their enthusiasm with coronavirus-related stocks, driving Moderna (MRNA +15.6%) up on almost triple normal volume. At a news conference today, a U.S. health official stated that there have been no "glitches" in development to date with the company's investigational coronavirus vaccine (company is working with NIH).
  • Two weeks ago, it announced funding from a public-private coalition to support the manufacture of the vaccine.
  • Fellow mRNA therapeutics developer Alnylam Pharmaceuticals (ALNY +3%) is up as well, albeit on average volume.
  • Update: The official stated that the vaccine could be ready for a Phase 1 study in 2 1/2 months.

Recommended For You

Comments (7)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.